Chitkara University joins hands with blue-chip IT giant Virtusa to offer Master's Program in Computer Science & Engineering
Chitkara University announced the launch of a two-year MSc Program in Pharmacovigilance & Clinical research, in collaboration with Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from clinical through commercialization.
The program is aimed at addressing the concern of talent crunch in the Pharmacovigilance industry and contributes towards building the research and development capacity of India.
The two-year master's degree program in Pharmacovigilance & Clinical research is designed to create skilled and competent professionals who can work effectively at different levels in Pharmacovigilance departments of leading Pharma companies and Clinical Research Organizations (CROs) in India as well as around the world.
Parexel, a leading CRO, will provide industry and curriculum support from its Parexel Academy as a part of the collaboration.
"We have always had a strong focus in growing India as a clinical operational hub supporting both our local and global drug development. The clinical research industry has seen a tremendous boost in recent years and this growth requires strong skill sets and talent to help bring new therapies to market. To develop this talent requires combined practical and academic experience. With this partnership with Chitkara University Parexel hopes to help develop the future workforce of the clinical research industry, that will be instrumental in shaping the future of R & D in India and supporting the needs of patients," said Sanjay Vyas, Senior Vice President, India Country Head & Head CTS & L, Parexel International, on the collaboration.
"The two-year MSc Program in Pharmacovigilance & Clinical research, offered in collaboration with Parexel, is an outcome of Chitkara University's relentless focus on offering programs designed and delivered in conjunction with the industry leaders and contribute to nation-building by developing indigenous talent. Chitkara University affirms its support to the Prime Minister's mission of 'Atmanirbhar Bharat'. This collaboration will ensure that the curriculum is dynamic and tailored to the constantly evolving industry trends. Students get exposure to the industry's best practices during their degree," said Dr Madhu Chitkara, Pro-Chancellor of Chitkara University.
Program and curriculum
The industry-led curriculum includes an in-depth study of Pharmacovigilance related processes, complemented with hands-on training on advanced ICSR processing, quality management, Pharmacovigilance medical safety writing, aggregate report (PSUR/PBRER/PADER, etc.) writing and compliance management.
The program will expose students to the internationally compliant Pharmacovigilance training based on defined Pharmacovigilance Competency Frameworks (PCF) and help develop internationally accepted competencies, under the mentorship of industry leaders.
Continuous and timely interaction with industries including leading Pharmaceutical companies and CROs (nationally and internationally), and government organizations for academics, conferences, and placements are an integral part of this program.
The second year has been designed to include specialization centric studies and internship opportunities in industry settings, either in association with a clinical research organization or a Pharmaceutical company.
The students graduating from this program can find employment as Pharmacovigilance Scientists, Pharmacovigilance Quality Reviewers, Pharmacovigilance Quality Analysts, Pharmacovigilance Medical Safety Writers, Pharmacovigilance System Specialists, etc.
The past two decades have witnessed an unprecedented increase in the prevalence of chronic diseases such as oncological diseases, diabetes, and cardiovascular, respiratory, and lifestyle disorders have led to a rise in drug consumption worldwide.
With increasing patient count, the incidents of Adverse Drug Reactions (ADRs) are expected to accelerate the demand for Pharmacovigilance services, which is now an inevitable part of drug discovery and development procedures.
The global pharmacovigilance market size was estimated at USD 4.87 billion in 2019 and is expected to witness a CAGR of 13.2 per cent over the next ten years.
Parexel is focused on supporting the development of innovative new therapies to improve patient health. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients.
From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit our website and follow us on LinkedIn, Twitter and Instagram.
Parexel is a registered trademark of Parexel International Corporation. All other trademarks are the property of their respective owners.
Chitkara University, situated near Chandigarh, has emerged as the most vibrant and high-ranking University in North India. The University offers courses in Engineering & Technology, Business, Planning & Architecture, Art & Design, Mass Communication, Sales & Marketing, Hospitality Management, Pharmacy, Health Sciences, and Education.
University's ranking laurels include getting featured in the Prestigious Times Higher Education Impact rankings 2020, 26th rank in the DataQuest's 'Top 100 T Schools in India-2020' survey, ranked among top 25 universities in ARIIA 2020 by government of India and Chitkara Business School achieving 43rd rank in the BusinessWorld's coveted 'Top B-Schools-2019' survey, and 35th rank in the OUTLOOK I care B-School rankings 2020.
With state-of-the-art infrastructure, scientifically driven pedagogy, and strong industry collaborations, Chitkara University attracts the most exceptional students from across the nation and, with its seamless placement support, is also able to help them carve high growth careers.
This story is provided by NewsVoir. ANI will not be responsible in any way for the content of this article.